Jackson Creek Investment Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,039 shares of the specialty pharmaceutical company’s stock, valued at approximately $652,000. Several other hedge funds […]
StockNews.com lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from a strong-buy rating to a buy rating in a report released on Monday. A number of other equities analysts have also recently commented on the stock. Raymond James initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 28th. They […]
Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research report released on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $160.00 price objective on the specialty pharmaceutical company’s stock. Several other analysts also recently issued reports on the company. Truist Financial restated […]
Compass Wealth Management LLC trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 5.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,500 shares of the specialty pharmaceutical company’s stock after selling 335 shares during the quarter. Compass Wealth Management LLC’s holdings in Jazz Pharmaceuticals were worth $712,000 as […]
Truist Financial reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $200.00 target price on the specialty pharmaceutical company’s stock. A number of other equities research analysts have also recently issued reports on JAZZ. HC […]